Cornell University

Tri-institutional Therapeutics Discovery Institute

Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Other

The Rockefeller University

Rei Okamoto

Toshihiro Imaeda

Gang Herbert Lin

Carl F Nathan

Tzu-Tshin Wong

Kenjiro Sato

Yoshito Terao

Michael Andrew Foley

Takafumi Yukawa

Kazuyoshi Aso

Wenhu Zhan

Trevor Morgan

Ryoma Hara

Nobuyuki Matsunaga

Yasushi Hattori

Tatsuki Koike

Tsuneo Oda

Takahiro Sugimoto

Yasutaka Hoashi

Junya Shirai

Norihito Tokunaga

Xiaolun Wang

Yoshiteru Ito

Yuichi Kajita

Keisuke Imamura

Tomohiro Okawa

Yuhei Miyanohana

Nicholas Scorah

Keiko Kakegawa

Minoru Yoshida

John S Tyhonas

Terufumi Takagi

Mark Sabat

Phong H Vu

Tohru Miyazaki

Yasufumi Miyamoto

Koichiro Fukuda

Kohei Takeuchi

Akito Shibuya

Joanne Miura

Zenyu Shiokawa

Yuta Tanaka

Yoichi Nishikawa

Haixia Wang

Naoki Miyamoto

Lily Kwok

Mallareddy Komandla

Yasuhisa Kohara

Akinori Toita

Takeshi Yoshikawa

Taiichi Ohra

Takashi Nakahata

Laura Kirkman

Hiroki Takahagi

Dilhumar Uyghur

Mayako Michino

Masanori Kawasaki

John D Ginn

Paul Tanis

Takeshi Yamamoto

Thomas Tuschl

Hideo Suzuki

Hidekazu Tokuhara

Yasutomi Asano

Taku Kamei

Jumpei Aida

Dinshaw J Patel

Jochen Buck

Lonny Levin

Kouhei Asano

Ayumu Sato

Takanobu Kuroita

J Fraser Glickman

Jun Chiba

Lodoe Lama

Michael Miller

Shogo Hashizume

Daisuke Tomita

Lavoisier Ramos-Espiritu

Clemens Steegborn

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I′): where the substituents R, R, R, R, R, R, R', R″, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R', R″, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Macrocyclic compounds as proteasome inhibitors

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R, R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, R, R, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Peptidomimetic proteasome inhibitors

1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.

Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, RR, R&#x2032;, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues. 

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

Provided are 6-amino substituted 2,6-diamino-4-chloropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The compositions can be used for treatment of various conditions including ocular hypotony.

Inhibitors of soluble adenylyl cyclase

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. The present invention relates to a compound represented by the following formula: wherein each symbol is as defined in the specification, or a salt thereof.

[object Object]

Growing community of inventors

Kanagawa, Japan

Rei Okamoto